Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228084 | 0.89 | L3MBTL1 (0.43) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL31407376 | 0.85 | PIM1 (0.42) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL1710746 | 0.85 | PIM1 (0.42) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL1587770 | 0.85 | PIM1 (0.42) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL29955151 | 0.84 | L3MBTL1 (0.44) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL29443994 | 0.83 | MEN1 (0.41) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL12723412 | 0.83 | PIM1 (0.41) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL15902516 | 0.83 | MEN1 (0.41) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL19260896 | 0.80 | ELANE (0.44) | L3MBTL1PIM1MARK3MAP4K2CAMK2B | |
| SCHEMBL1196432 | 0.80 | L3MBTL1 (0.62) | L3MBTL1PIM1MARK3MAP4K2CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | L3MBTL1 3418/4885PIM1 3075/4885MARK3 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.